Here, TP53 mutation is detected in up to 75% of patients, while patients who harbor co-occurring mutations show a lower incidence of mutations in several AML-related genes such as NPM1, FLT3, IDH1, IDH2, WT1, DNMT3A, RUNX1, and RAS [33, 34]. Here, NPM1 is linked to acute myeloid leukemia.